Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual Syndrome
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Three hundred women with severe premenstrual syndrome will be divided into 3 groups using
computer generated random numbers. Group 1 will receive COC containing drospirenone
(drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® ScheringAG, Egypt) daily for 21 days
starting from the 3rd day of menstruation in addition to oral fluoxetine 20 mg daily. Group 2
will receive COC containing drospirenone daily for 21 days starting from the 3rd day of
menstruation in addition to a daily oral placebo similar in size, color and structure to
fluoxetine . Group 3 will receive oral placebo similar to COC daily for 21 days starting from
the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and
structure to fluoxetine.